These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 26754001)

  • 1. RASSF1 tumor suppressor gene in pancreatic ductal adenocarcinoma: correlation of expression, chromosomal status and epigenetic changes.
    Amato E; Barbi S; Fassan M; Luchini C; Vicentini C; Brunelli M; Malleo G; Scarpa A; Malpeli G
    BMC Cancer; 2016 Jan; 16():11. PubMed ID: 26754001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma.
    Byun DS; Lee MG; Chae KS; Ryu BG; Chi SG
    Cancer Res; 2001 Oct; 61(19):7034-8. PubMed ID: 11585730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylation-associated down-regulation of RASSF1A and up-regulation of RASSF1C in pancreatic endocrine tumors.
    Malpeli G; Amato E; Dandrea M; Fumagalli C; Debattisti V; Boninsegna L; Pelosi G; Falconi M; Scarpa A
    BMC Cancer; 2011 Aug; 11():351. PubMed ID: 21838870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma.
    Lee MG; Kim HY; Byun DS; Lee SJ; Lee CH; Kim JI; Chang SG; Chi SG
    Cancer Res; 2001 Sep; 61(18):6688-92. PubMed ID: 11559536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early epigenetic downregulation of WNK2 kinase during pancreatic ductal adenocarcinoma development.
    Dutruel C; Bergmann F; Rooman I; Zucknick M; Weichenhan D; Geiselhart L; Kaffenberger T; Rachakonda PS; Bauer A; Giese N; Hong C; Xie H; Costello JF; Hoheisel J; Kumar R; Rehli M; Schirmacher P; Werner J; Plass C; Popanda O; Schmezer P
    Oncogene; 2014 Jun; 33(26):3401-10. PubMed ID: 23912455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant methylation of RASSF2A in human pancreatic ductal adenocarcinoma and its relation to clinicopathologic features.
    Zhao L; Cui Q; Lu Z; Chen J
    Pancreas; 2012 Mar; 41(2):206-11. PubMed ID: 21792082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
    Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
    Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic regulation and role of metastasis suppressor genes in pancreatic ductal adenocarcinoma.
    Mardin WA; Haier J; Mees ST
    BMC Cancer; 2013 May; 13():264. PubMed ID: 23718921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant methylation of the 5' CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanlNs.
    Jansen M; Fukushima N; Rosty C; Walter K; Altink R; Heek TV; Hruban R; Offerhaus JG; Goggins M
    Cancer Biol Ther; 2002; 1(3):293-6. PubMed ID: 12432281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased expression of RASSF1A and up-regulation of RASSF1C is associated with esophageal squamous cell carcinoma.
    Guo W; Cui L; Wang C; Guo Y; Shen S; Kuang G; Dong Z
    Clin Exp Metastasis; 2014 Jun; 31(5):521-33. PubMed ID: 24756244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased expression and promoter methylation of the menin tumor suppressor in pancreatic ductal adenocarcinoma.
    Cavallari I; Silic-Benussi M; Rende F; Martines A; Fogar P; Basso D; Vella MD; Pedrazzoli S; Herman JG; Chieco-Bianchi L; Esposito G; Ciminale V; D'Agostino DM
    Genes Chromosomes Cancer; 2009 May; 48(5):383-96. PubMed ID: 19170121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic Silencing of GNMT Gene in Pancreatic Adenocarcinoma.
    Botezatu A; Bleotu C; Nastase A; Anton G; Bacalbasa N; Duda D; Dima SO; Popescu I
    Cancer Genomics Proteomics; 2015; 12(1):21-30. PubMed ID: 25560641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High methylation levels of PCDH10 predict poor prognosis in patients with pancreatic ductal adenocarcinoma.
    Curia MC; Fantini F; Lattanzio R; Tavano F; Di Mola F; Piantelli M; Battista P; Di Sebastiano P; Cama A
    BMC Cancer; 2019 May; 19(1):452. PubMed ID: 31088413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
    Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
    Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer.
    Fiolka R; Zubor P; Janusicova V; Visnovsky J; Mendelova A; Kajo K; Lasabova Z; Plank L; Danko J
    Oncol Rep; 2013 Dec; 30(6):2878-86. PubMed ID: 24068440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased expression of RASSF1A tumor suppressor gene is associated with worse prognosis in clear cell renal cell carcinoma.
    Klacz J; Wierzbicki PM; Wronska A; Rybarczyk A; Stanislawowski M; Slebioda T; Olejniczak A; Matuszewski M; Kmiec Z
    Int J Oncol; 2016 Jan; 48(1):55-66. PubMed ID: 26648328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.
    Tomizawa Y; Kohno T; Kondo H; Otsuka A; Nishioka M; Niki T; Yamada T; Maeshima A; Yoshimura K; Saito R; Minna JD; Yokota J
    Clin Cancer Res; 2002 Jul; 8(7):2362-8. PubMed ID: 12114441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas.
    Dammann R; Takahashi T; Pfeifer GP
    Oncogene; 2001 Jun; 20(27):3563-7. PubMed ID: 11429703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.
    Spugnardi M; Tommasi S; Dammann R; Pfeifer GP; Hoon DS
    Cancer Res; 2003 Apr; 63(7):1639-43. PubMed ID: 12670917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas.
    Hesson L; Bièche I; Krex D; Criniere E; Hoang-Xuan K; Maher ER; Latif F
    Oncogene; 2004 Mar; 23(13):2408-19. PubMed ID: 14743209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.